Form D · Pharmaceuticals
Nuvation Bio Inc.
New York, NY · CIK 0001829093
Offering snapshot reported Oct 20, 2020 · SEC filing
- Reported sold
- $275M Offering amount: $275M
- Investors reported
- 57 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 17, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 20, 2020 | Initial | $275,348,195 | No comparison | 57 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-378335
Includes $15,000,000 in value of cancelled convertible instruments.
Source: Form D, filed Oct 20, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Bazemore | Director |
| Kim Blickenstaff | Director |
| Michelle Doig | Director |
| Kathryn E. Falberg | Director |
| David Hung, M.D. | Director, Executive |
| Claudio Nessi | Director |
| W. Anthony Vernon | Director |
| Daniel Welch | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1500 Broadway Suite 1401
New York, NY, 10036
New York, NY, 10036